Search

We present a high-scale method to produce few-layer graphene (FLG) based on the mechanical exfoliation of graphite and compare the obtained FLG with the one reported earlier arising from pencil lead ablation. Several elements were modified and improved in the new approach. The purification and the ablation set-up were simplified, and the morphology of the FLG was modified and improved in view of some applications. The morphology-dependent properties of FLGs, lead-FLG, and graphite-FLG as conductive layers and in nanocomposites were investigated. The newly obtained FLG had a higher aspect ratio (high lateral size vs thickness/higher 2D aspect), which is reflected by enhanced transparency–conductivity features of the layer (film) and elongation-at-break behavior of the polymer composites. On the contrary, the nanocomposite containing lead-FLG showed, for instance, excellent gas barrier properties due to the multi-step structure of the lead-FLG flakes. Such structure exhibited less 2D and more 3D character, which can be highly suitable for applications where the presence of active/reactive edges is beneficial, e.g., in catalysis or supercapacitors’ electrodes. Nuclear reaction analysis was employed to investigate the morphology of graphite-FLG film.

Polydopamine (PDA) deposition, obtained from the oxidation of dopamine and other catecholamines, is a universal way to coat all known materials with a conformal coating which can subsequently be functionalized at will. The structural analogies between polydopamine and eumelanin, the black-brown pigment of the skin, were incited to produce stable polydopamine nanoparticles in solution, instead of amorphous precipitates obtained from the oxidation of dopamine. Herein, we demonstrate that size-controlled and colloidally stable PDA-based nanoparticles can be obtained in acidic conditions, where spontaneous auto-oxidation of dopamine is suppressed, using sodium periodate as the oxidant and a protein, like alkaline phosphatase (ALP), as a templating agent. The size of the PDA@ALP nanoparticles depends on the dopamine/enzyme ratio and the obtained particles display enzymatic activity of alkaline phosphatase, with an activity extending up to two weeks after particle synthesis. The PDA@ALP nanoparticles can be engineered in polyelectrolyte multilayered films to potentially design model biosensors.

Iron oxide nanoparticles are widely used as a contrast agent in magnetic resonance imaging (MRI), and may be used as therapeutic agent for magnetic hyperthermia if they display in particular high magnetic anisotropy. Considering the effect of nanoparticles shape on anisotropy, a reproducible shape control of nanoparticles is a current synthesis challenge. By investigating reaction parameters, such as the iron precursor structure, its water content, but also the amount of the surfactant (sodium oleate) reported to control the shape, iron oxide nanoparticles with different shape and composition were obtained, in particular, iron oxide nanoplates. The effect of the surfactant coming from precursor was taking into account by using in house iron stearates bearing either two or three stearate chains and the negative effect of water on shape was confirmed by considering these precursors after their dehydration. Iron stearates with three chains in presence of a ratio sodium oleate/oleic acid 1:1 led mainly to nanocubes presenting a core-shell Fe1−xO@Fe3−xO4 composition. Nanocubes with straight faces were only obtained with dehydrated precursors. Meanwhile, iron stearates with two chains led preferentially to the formation of nanoplates with a ratio sodium oleate/oleic acid 4:1. The rarely reported flat shape of the plates was confirmed with 3D transmission electronic microscopy (TEM) tomography. The investigation of the synthesis mechanisms confirmed the major role of chelating ligand and of the heating rate to drive the cubic shape of nanoparticles and showed that the nanoplate formation would depend mainly on the nucleation step and possibly on the presence of a given ratio of oleic acid and chelating ligand (oleate and/or stearate).